Graft-versus-host disease (GvHD) caused by alloreactive T cells within the graft is a major drawback of allogeneic BMT, but depletion of T cells leads to higher rates of relapse, opportunistic infections and graft failure. Therefore, selective removal of GvHD-inducing alloreactive T cells might be beneficial. We describe here the separation of alloresponsive T cells, based on carboxyfluorescein succimidyl ester labeling, in vitro allostimulation and FACS-sorting. In vivo effects of the separated cell populations were investigated in the context of allogeneic BMT in murine models: in vitro resting T cells were shown to survive in the allogeneic host and retain immunoreactivity against 'third-party' antigens. As demonstrated in two different transplantation models, elimination of proliferating cells significantly reduces GvHD but offers no advantages to using T-cell-depleted bone marrow alone concerning engraftment and tumor control. Transplanting T cells that proliferate in response to tumor antigens in vitro may narrow down the spectrum of antigens recognized by T cells and therefore reduce GvHD while maintaining graft-facilitating function and tumor control. Therefore, selecting tumor-reactive T cells on the basis of their proliferative response in vitro may be beneficial for the recipient, less time consuming than T-cell cloning and still reduce the extent of GvHD.
Introduction
Allogeneic bone marrow (BM) transplantation is an established procedure for a variety of diseases of the hematopoietic system, including leukemia, lymphoma and autoimmune diseases. 1 The treatment is hampered by the development of acute and chronic graft-versus-host disease (GvHD), which is induced by alloreactive T cells within the graft or given separately as a donor lymphocyte infusion (DLI) (reviewed by Ferrara et al.
2
) and has a profound impact on survival and quality of life. T cells, on the other hand, confer a protective effect against relapse of the underlying malignant disease 3, 4 and support engraftment. 5, 6 Therefore, an increasing arsenal of immunosuppressive agents is used for GvHD prophylaxis in the clinical application of BM transplantation. 7, 8 The complete elimination of T cells in the graft represents an efficient means to circumvent GvHD induction, but leads to increased relapse rates, 3 impaired engraftment 9 and profound immunosuppression, resulting in increased mortality caused by opportunistic infections. 10 Repetitive infusion of increasing amounts of donor T cells (DLI 11 ) at intervals after transplantation of T-cell-depleted (TCD) BM proves to be valuable for the treatment of relapse but still bears the risk of GvHD induction. Therefore, in vitro approaches to selectively eliminate alloreactive T cells have been developed: they include removal of activated CD25 þ T cells, 12 CD69-positive cells, 13 induction of activation-induced cell death by treatment with anti-CD95 antibodies 14 and the depletion of proliferating cells using photodynamic labeling. 15 In vivo elimination of alloreactive T cells after TK suicide gene modification 16 or the addition of expanded regulatory T cells 17, 18 was also evaluated. The strategy of identifying leukemia-specific or lineage-specific minor antigens on malignant host cells 19, 20 may allow selective induction of leukemia-reactive T cells with low alloreactivity but is labor-intensive and time consuming.
In this study, we evaluated a carboxyfluorescein succimidyl ester (CFSE)-based method 21 to deplete alloreactive T cells by ex vivo stimulation and subsequent selection of non-proliferating T cells. The approach is based on the observation that T cells proliferate in response to allogeneic stimuli 22 and display a distinct phenotype. 23 CFSE labeling and allostimulation allow the reliable identification and FACS-based separation of resting and proliferating T cells via dye dilution of the latter. Resting T cells have been shown to be tolerant towards their stimulators in vitro and in vivo, but remain responsive to 'third-party' stimuli and antigens from viral and fungal pathogens. 24 Although immune reconstitution was augmented as judged by mixed lymphoid chimerism and B-cell recovery, in vivo function of these cells concerning engraftment and tumor control was not detectable.
On the other hand, using CFSE-labeled and subsequently FACS-selected tumor-responsive T cells in a minor mismatch model elimination of resting cells may attenuate GvHD, whereas proliferating cells support engraftment and tumor control.
Materials and methods
Mice C3H, BALB/c, DBA/2 and C57BL/6 mice were bought from Harlan (Borchen, Germany) and kept in conventional caging. Rag1
À/À mice backcrossed more than 10 generations on a C57BL/6 (B6) background were kindly provided by Professor T Blankenstein, MDC, Berlin, and housed in sterilized individually ventilated cages. Experimental procedures were performed according to German federal and state regulations as well as the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All mice strains were subjected to regular health status controls and were free of commonly tested viruses, parasites and bacteria. The age of mice used in experiments ranged from 6 to 12 weeks.
Tumor cells P815, mouse mastocytoma on DBA/2 background, 25 was obtained from ATCC (Rockville, MD, USA); P815B7 (kindly provided by P Fields, University of Chicago, Chicago, IL, USA) is rejected in a CD8
þ T-cell-dependent fashion. 26 EB, a DBA/2 lymphoma line, was kindly provided by Professor T Blankenstein, MDC Berlin, Germany.
T-cell culture and mixed lymphocyte reaction Single-cell suspensions from spleens were prepared and 5 Â 10 6 cells in 2 ml were cocultured for 4 days with equal amounts of 20 Gy gamma-irradiated stimulator cells (homogenized splenocytes) or mitomycin-treated tumor cells as described elsewhere. 27 Culture medium was composed of RPMI1640, containing 1% L-glutamine, 1% penicillin/streptomycin, 0.01% b2-mercaptoethanol, 1% non-essential amino acids (all Gibco BRL Life Technologies, Karlsruhe, Germany) and 10% fetal calf serum (FCS, Sigma, Munich, Germany). For the second and higher passages, 6 IU/ml rhIL-2 (kindly provided by Dr O Krieter, Chiron Biopharmaceuticals, Munich, Germany) was added. Double staining of mixed lymphocyte reaction (MLR) with Thy-1 and CD3 revealed exclusive coexpression of both markers.
Antibodies and flow cytometry analysis
The following antibodies were purchased from Pharmingen, San Diego, CA, USA: anti-CD8-a-biotin (53-6.7), anti-CD4-biotin (Gk1.5) and anti-CD25-biotin (7D4), anti-B220-PE (RA3-6B2), anti-CD5.1-FITC (H11-86.1), anti-rat IgG-2b-FITC (RG7/11.1) and rat IgG2b Isotypecontrol-Ab (A95-1), anti-K k -FITC (16-3-22.4) and anti-K d -PE (SF1-1.1). Anti-CD3-FITC (145-2C11), anti-CD8-a-PE (53-6.7) and anti-CD4-FITC (Gk1.5) were from Southern Biotechnology, Birmingham, AL, USA. Hybridoma supernatants were collected from the following hybridomas: antiMac-1 (RB8-5C6), anti-FcgR II/III (2.4G2) and anti-Gr-1 (RB6-8C5) (were purchased from ATCC (Rockville, MD, USA); biotinylated anti-Thy-1 (5a-8) and SA-PE-Cy7 were purchased from Caltag Laboratories (Burlingame, CA, USA), anti-Thy1.2-PE (30-H12) was from DPC Biermann, Bad Nauheim, Germany and immunomagnetic beads coupled with anti-Thy-l (30H12), anti-CD8 and anti-FITC (mouse IgG1) were from Miltenyi Biotech (BergischGladbach, Germany).
Immunostaining was preceded by Fc-R blocking with 2.4G2 hybridoma supernatant or preincubation with concentrated human Ig (Gammagard, Baxter Hyland Immuno, Heidelberg, Germany), when non-conjugated rat IgG2b antibodies were used as primary antibody. 5 Â 10 5 viable cells per sample, isolated from spleen and BM cells, were incubated for 15 min at 41C with the indicated antibodies. The antibodies were either directly conjugated or biotinylated to be incubated with streptavidin conjugate (PECy7) as second-step reagents. This was followed by two washes (PBS containing 2.5% FCS and 1% sodium azide) between incubations. Viable lymphocytes were gated by either forward or side scatter and propidium iodide dye exclusion and three-color fluorescence analysis was performed on 10 000 live cells using a FACS-SCAN and Cell-Quest Software (Becton Dickinson, BD Biosciences, Heidelberg, Germany). Isotype controls as well as negative and positive controls were regularly used.
CFSE labeling and cell separation
A single-cell suspension of responding splenocytes (C3H or BALB/c) was labeled in 3 mM carboxyfluorescein diacetate succimidyl ester (CFSE) according to the manufacturer's recommendations (Molecular Probes, Eugene, OR, USA) and subsequently stimulated for 4 days. Proliferation of T cells was documented after 3 days of culture, counterstaining with biotinylated anti-Thy-1 and SA-PECy7 and FACS analysis. After enrichment of viable lymphocytes by density gradient centrifugation on Lympholyte-M (Cedarlane, Hornby, Ontario, Canada) for 30 min at 1500 g, proliferating (CFSE-'low' fraction) and resting (CFSE-'high' fraction) T cells (Thy-1 þ ) were FACS-sorted on a Coulter Epics Altra and Expo32 software (Beckman Coulter, Stanford, CA, USA). Resting fractions were readily separable from non-proliferating cells as mean fluorescence of these two clearly distinct fractions differed by at least 2 logs. 3 [H]Thymidine incorporation assay 'High' cells were generated in vitro by stimulation and cell sorting as described above. MHC-identical model BALB/c-DBA/2. BALB/c donor mice were preimmunized with 10 7 DBA/2 spleen cells (or P815B7 tumor cells irradiated with 100 Gy) to increase the amount of responding T cells and subsequently labeled and in vitro stimulated as described above. Lethally irradiated mice received 14 Gy total body irradiation in three equal doses (within 48 h to reduce gastrointestinal toxicity); the last dose was given 18 h before BMT. BM cells (10 7 ) were injected i.v. after T-cell depletion as described above.
Evaluation of GvHD and engraftment
Mice were monitored every other day for weight and outer appearance (ruffled fur, reduced motor activity) and killed either on imminent death or on indicated time points. At least three independent experiments with three mice per group were performed (if not mentioned otherwise). Mice were analyzed between day 7 and day 10 post transplantation in the MHC-disparate model or when signs of GvHD were observable in at least one animal per group (starting on day 30 in the MHC-identical setting). Equal numbers of mice of each group were killed and analyzed (in the MHCidentical model). Data were compiled for analysis. Splenocytes and BM cells were counted, total cell numbers per organ calculated and further examined by FACS analysis for the expression of CD3/Thy-1, CD4, CD8, B220, Gr-1 and MHC I (K d and K k ). In the minor mismatch model, CD5.1 expression on DBA/2 T lymphocytes was used to document lymphoid chimerism. Percentage of chimerism was calculated as (% of CD5.1
Histological analysis
Tissues from the liver, spleen, intestine, lungs, tongue and ear were fixed in 4% paraformaldehyde, embedded in paraffin and hematoxylin-eosin-stained tissue sections were analyzed. Naı¨ve C3H and DBA/2 mice as well as DBA/2 mice receiving syngeneic transplants were used as controls.
Cytotoxicity assays
Fresh splenocytes or cells from culture were measured for CTL activity in a standard 51 Cr-release assay using 51 Crlabeled DBA/2 mastocytoma line P815 or DBA/2 lymphoma line EB as labeled targets following general procedures described previously. 28 Each culture was assayed in duplicate at six double dilutions. Variation in gamma counts between the duplicates was less than 5% of the means in all experiments; means of the results obtained in duplicate were used to calculate the 51 Cr release or percent lysis for each dilution using the following formula: % lysis ¼ ((experimental releaseÀspontaneous release)/(maximum releaseÀspontaneous release)) Â 100.
Tumor inoculation
To evaluate the potential of transplanted T-cell fractions to control the outgrowth of an immunogenic tumor, P815B7 was used as a tumor model. This tumor, expressing murine B7, is inevitably rejected in a CD8
þ T-cell-dependent manner in BALB/c and DBA/2 mice when injected s.c. 26 The tumor grows progressively in lethally irradiated mice receiving TCD BM only. Mice were inoculated with either 2 Â 10 6 or 5 Â 10 5 tumor cells a day before irradiation as indicated. Tumor growth was monitored three times a week in three perpendicular diameters using calipers. Tumor volume was calculated by using the formula (abc/2) and mice were killed when tumor size exceeded 1.5 cm in diameter.
Results
Phenotype and cytolytic activity of resting and proliferating T cells after allostimulation and separation in vitro Alloreactive T cells divide when responding to allogeneic stimuli, whereas those not responding do not proliferate in vivo. 22, 23 Based on this observation, we used an in vitro fluorescent dye dilution method (CFSE) to identify alloreactive T cells. To determine appropriate in vitro conditions for T-cell stimulation and CFSE labeling, dose and stimulation time defining experiments were performed: Sufficient separation efficiency and a high yield of T cells in either fraction are obtained after 4 days of stimulation ( Figure 1a ). FACS analysis of these MLR cultures with anti-Thy-1, CD4 and CD8 did show presence of these markers on cells of either fraction (Figure 1b ). CD25 expression can be detected in CFSE-'high' and CFSE-'low' fractions ( Figure 1b ). Non-dividing T cells did show a small non-granular phenotype, whereas cycling T cells were of granular blastoid phenotype ( Figure 1c) .
Applying equal amounts of FACS-separated T cells in a chromium release assay directed against the initial in vitro stimulator, we detected cytolytic activity against allogeneic DBA/2 target cells of proliferating splenic C3H T cells but not resting T cells (Figure 1d ). Therefore, we assumed that the CFSE-'high' fraction is tolerant towards recipient cells and might not induce destruction of allogeneic tissue (GvHD) when transplanted into an irradiated host, whereas cells of the 'low' fraction should do so.
Resting 'high' T cells retain responsiveness to 'third-party' stimuli in vitro, and are active after transplantation and reisolation Transplanting tolerant allogeneic T cells will only be beneficial for the recipient, when reactivity against infectious agents and the underlying malignant disease is maintained. To explore whether 'high' cells are still able to respond to unrelated stimulators after 4 days of culture against the 'primary' stimulator, we restimulated the sorted fraction with 'third-party' allogeneic irradiated splenocytes (C57BL/6) or infectious agents such as CMV-and C. albicans antigens. The proliferative response of these T cells was analyzed in a 3 [H]thymidine incorporation assay.
As shown in Figure 2a , 'high' T cells do remain responsive towards 'third-party' and infectious antigens. Compared to unstimulated 'high' cells, there is a twofold increase in proliferation towards C57BL/6 splenocytes. When stimulated with CMV or Candida, the increase is even higher, 2.5-to 3-fold, respectively. These results suggest that in vitro resting 'high' cells maintain immunologic functions such as response against 'third-party' antigens.
To address the question whether transplanted resting T cells maintain this responsiveness in vivo, donor C3H 'high' T cells, reisolated from DBA/2 recipients 7 days after transplantation and subsequently restimulated in vitro, were assayed for 'third-party' reactivity. As depicted in Figure 2b , reisolated T cells proliferate after CFSE labeling and in vitro restimulation, whereas no activity against host DBA/2 splenocytes was detectable. Remaining recipient K d þ -Thy-1 þ cells did not proliferate upon stimulation (data not shown). In the majority of control animals having received BM alone, spleens did not contain T cells of donor origin (see Figure 3a) , documented by the absence of Thy1 þ and K k þ cells. This led to the conclusion that at Figure 3c ) were detectable, whereas spleens of mice transplanted with TCD BM cells alone did not contain donor-derived T cells (Figure 3a) . Spleens of 'low' fraction recipients are virtually devoid of any host-derived cells (Figure 3e) , and T cells of donor origin, expressing a donor class I molecule (K k þ ), predominate (Figure 3e ). An even stronger effect of active destruction of host tissue can be seen after transfer of unseparated MLR T cells (Figure 3g ). Spleens of mice receiving BM alone or additionally the 'high' T-cell fraction contain a fraction of Thy-1 À K kÀ cells (Figure 3a and c, left lower quadrant), which mainly consisted of granulocytes and monocytes (as judged by Gr-1 staining, a murine monocyte and granulocyte surface molecule; 29 data not shown). This documents that some myeloid cells of recipient origin remain, whereas spleens of animals having received the 'low' or unseparated MLR fractions mainly contain donor-derived T cells (Figure 3e and g ).
We therefore assume that host splenocytes which were used as initial stimulators in vitro are a biologically relevant target of 'low' T-cell fractions as well as of unseparated MLR T cells. 'High' T cells on the other hand are tolerant towards host-derived cells, including lymphocytes, granulocytes and monocytes, allowing those that survive TBI to remain and induce a mixed chimerism. Detection of a significant amount of ('high') allogeneic T cells suggests their repopulating capacity despite their reduced capacity to proliferate upon direct stimulation with DBA/2 spleen cells in vitro.
Splenic engraftment in the MHC-disparate transplantation model is summarized in Table 1 . It further underlines that transfer of the 'low' MLR fraction led to complete chimerism equivalent to transfer of non-separated MLR T cells, whereas transfer of the 'high' fraction led to the development of mixed chimerae. On examining the entire leukocyte population in the spleen, no significant differences were detectable between mice receiving TCD BM alone and those receiving 'high' cells in addition (Table 1) . Nevertheless, transferred T cells of the 'high' fraction engraft and survive as an increase in the percentage of donor T cells is detectable in recipient spleens. parameter for the extent of GvHD and support the concept that culturing alloresponsive T cells still maintains their potential to respond against recipient lymphopoiesis.
In vitro resting cells do not cause organ destruction in liver and spleen after transplantation To further evaluate the potential of GvHD-induction by the different T-cell fractions, liver sections were analyzed for necrosis and infiltrates of leukocytes. In liver tissue of 'high' fraction recipients, hardly any organ destruction was visible ( Figure 4 , upper left). However, recipients of the 'low' fraction showed a periportal leukocyte infiltration and necrosis ( Figure 4 , upper right). Comparable observations were made when spleen tissue sections were analyzed: Splenic architecture was completely destroyed in recipients of 'low' (Figure 4 , lower right) and 'MLR' fractions, harboring very few cells (arrows) that were exclusively T cells of donor origin. In 'high' fraction recipients, significant amounts of myelopoiesis (megakaryocytes, Figure 4 , lower left arrow) and cells of host origin were seen (Figure 3c ). This documents a diminished alloreactivity against liver and spleen tissue in this animal model in vivo.
'High' T-cell fractions do not facilitate engraftment in a minor mismatch model As allogeneic BM transplantation in the clinical setting is mainly performed in MHC-identical minor mismatch constellations and no survival advantages were demonstrable in the model system described above, the question was addressed whether proliferation-based T-cell separation does offer any advantages in an MHC-identical model system compared to transplantation of unseparated T-cellfractions or BM alone. Using the BALB/c-DBA/2 (both H2 d ) transplantation model, we transferred equal numbers of separated T cells in addition to 1 Â 10 7 TCD BM cells. Mice were killed when weight loss of more than 10% of the initial body weight or clinical signs of GvHD (reduced activity, hunched posture, ruffled fur) were detectable. As shown in Table 2 , engraftment of donor lymphopoiesis was not supported by 'high' T cells and development of full chimerism occurred with the same kinetics as in recipients of BM alone. On the other hand, addition of unsorted MLR T cells or the 'low' fraction rapidly led to complete lymphatic chimerism of recipients, suggesting an active role of transferred T cells on recipient lymphocytes. These findings reproduce the results obtained in the MHCdisparate model.
Weight loss and B-cell development in the BM as an indicator of GvHD development in the minor mismatch model
In contrast to previously published observations for the inverse constellation (DBA/2-BALB/c), 32 GvHD did not lead to rapid death of transplant recipients in the BALB/ c-DBA/2 model but to a clinical course equivalent to chronic GvHD. First clinical signs of GvHD like loss of weight (Figure 5a ), ruffled fur and hunched back became obvious starting about 30 days after transplantation. To further evaluate the potential of induction of 'lymphohematopoietic' GvHD, 33 we measured the absolute amount of B cells in both femora and tibial bones by multiplying the total number of viable cells obtained after flushing the bones with the percentage of B220 and surface-IgMpositive cells measured via FACS. As shown in Table 2 , B lymphopoiesis in the marrow in this model did not reach a significant level until day 30 post transplantation, but regularly exceeded 10 6 cells by day 30 when BM was transplanted either alone or with the 'high' T-lymphocyte fraction. On the other hand, T cells in the 'low' fraction or in MLR significantly suppressed B-cell development in the BM, demonstrating their potential to induce a chronic GvHD. Absence of B220 þ cells and donor chimerism directly correlated with weight loss and outer appearance Weight is plotted as a percentage of initial weight and standard deviation was less than 5% in all groups. Recipients of BM alone (diamond) or BM plus 'high' T-cell fractions (triangle) are unaffected by the transplantation procedure and slowly gain weight, whereas 'MLR' (square) and 'low' (circle) recipients first show an acute decrease in weight, which may reflect an acute phase of GvHD, recover for a period of weeks and subsequently progressively lose weight (chronic GvHD). This correlates with absence of B220 þ cells in the BM presented in Table 2 . (b) Progression of an immunogenic tumor after allogeneic BM transplantation is dependent on alloreactive T cells. After tumor cell inoculation -before allogeneic transplantation and T-cell transfer -outgrowth was monitored. Whereas tumor growth is unaffected in recipients of the BM plus 'high' fraction (triangle) compared to BM alone (diamonds), outgrowth is retarded when the 'low' fraction (circle) is added to TCD BM. MLR cells plus BM (squares) mediate almost complete tumor control but induce GvHD.
(Cumulative data of all experiments performed are shown).
post transplantation, whereas mice without signs of GvHD progressively increased their weight (Figure 5a ).
'High' T cells are unable to influence tumor growth
To further evaluate the potential of transferred T-cell fractions regarding control of an underlying malignant disease, we inoculated 2 Â 10 6 P815B7 tumor cells s.c. and outgrowth was monitored post transplantation. As presented in Figure 5b , tumors grew as fast in mice receiving the 'high' fraction as in BM recipients. Neither group was able to reject any transplanted tumor, but in MLR and 'low' fraction recipients tumor growth rate was significantly diminished. To rule out effects of excess initial tumor burden post transplantation, mice were inoculated with 5 Â 10 5 (1/4 of initial cell dose) P815B7 tumor cells (data not shown). Tumor growth kinetics between recipients of BM alone and recipients of BM plus 'high' cells did not show relevant differences. In fact, growth curves are merely shifted along the time axis, when less tumor cells were inoculated, without differences in outgrowth kinetics.
GvHD reduction by transferring T cells primed against tumor cells
Although reactivity against antigens from pathogens is maintained in 'high' T-cell fractions, no significant biological activity on engraftment and tumor rejection was seen when these cells were transferred. Therefore, we evaluated whether narrowing the spectrum of antigens in the initial stimulator culture may lead to reduced potential of GvHD induction in the 'low' fraction. BALB/c splenocytes primed against P815B7 in vivo were used as responders against P815B7 tumor cells in vitro. Thy-1-positive proliferating cells ('low') were transferred and spleen and BM cell composition was compared on day 30 to recipients of T cells of unsorted mixed leukocyte-tumor cell culture (MLTC). FACS analysis revealed residual host lymphocytes in the spleen of mice that received tumor-reactive cells compared to MLTC recipients, who showed a complete donor chimerism (Figure 6a and c) . In addition, B-cell development in the BM was unaffected in the first group but clearly decreased in the latter (Figure 6b and d) . We conclude that enrichment of tumor-stimulated T cells may reduce the extent of GvHD when transferred in the context of an allogeneic BMT possibly owing to lack of antigens in the primary stimulator (P815B7), which are relevant for the induction of GvHD.
Effects of anti-lymphocyte-stimulated 'high'and 'low' allogeneic T-cell fractions in Rag 1 À/À mice To further evaluate the GvHD-inducing potential of 'low' cells primed against antigens less abundant in the host, C3H splenocytes were stimulated with irradiated B6 spleen cells, and MLR, 'high' and 'low' fractions were transferred into Rag1
À/À mice on a B6 background. These knockout mice are devoid of mature T and B cells owing to inactivation of their recombinase-activating gene-1 (Rag-1). 34 Therefore, if selection of T cells on the basis of proliferation is effective, lymphoreactive T cells should not induce GvHD in hosts without lymphocytes. Interestingly, 'low' recipients survived more than 120 days without any signs of GvHD, whereas survival of MLR and 'high' recipients was reduced ( Figure 7 ) and signs of GvHD were present. FACS analysis of peripheral blood taken on day 30 did show presence of K k -positive T cells in all mice (data not shown). This suggests that MLR and 'high' fractions respond to antigens in the Rag1 À/À host and induce GvHD. Concerning the 'high' fraction, this is probably due to antigens that are not preferentially present in B6 stimulator splenocytes. On the other hand, 'low' fraction T cells which are not stimulated in the Rag1 À/À host obviously do not respond to host antigens owing to absence of lymphocytes, used as initial stimulators. When the observation time of 120 days was exceeded, two out of four mice were challenged with 10 7 irradiated B6 splenocytes i.p. After 3 weeks, these mice died, whereas control animals did not show any complications. This observation could be in line with an activation and response of circulating C3H T cells specifically responding to target antigens for which they were initially selected for. This may suggest that C3H lymphocytes in the B6 host were not anergic but rather lacking antigens required for reactivation. It also suggests that when large quantities of antigen are present in hosts having received preselected T cells, lethal GvHD may be induced. Therefore, such a 'specific' response will not necessarily avoid development of GvHD.
Discussion
Allogeneic BM transplantation, an effective means to treat a variety of hematological malignancies, is hampered by the occurrence of GvHD, mediated by T cells within the graft, 8 which leads to significant acute and chronic toxicity, reducing survival and quality of life. 35 T-cell depletion is therefore an effective possibility to reduce the risk of GvHD but major drawbacks are higher risk of viral infections, graft failure 9 and relapse of the underlying disease. 3, 36 Therefore, multiple strategies of graft manipulation have been suggested to reduce the risk of GvHD without losing the graft-versus-leukemia (GvL) effect, 36 but so far, these strategies have not yet reached clinical applicability. As alloreactive T cells are identifiable via proliferation in vitro 24 and in vivo 23 using the intracellular dye CFSE, depletion of dividing T cells stimulated with alloantigen in vitro before transplantation seemed to be a promising approach to reduce the risk of GvHD and maintain protective T-cell functions against infection and the underlying disease. We describe here the in vivo effects of transplanted T cells -selected on the basis of their proliferative response -on GvHD induction, engraftment and hemolymphatic reconstitution, as well as their potential to reject immunogenic tumors. We can demonstrate survival of donor 'high' T lymphocytes in the host, which are tolerant towards host tissues but reactive against antigens of pathogens and restimulatable in vitro and in vivo. Nevertheless, they do not support donor cell engraftment and tumor control. B-cell recovery was not affected by transferring BM plus 'high' T cells, therefore further reducing the risk of infections of allograft recipients. 37, 38 Our results underline a possible function of alloresponsive, proliferating T cells in induction of complete chimerism 9 and GvHD, which cannot be replaced by T cells resting upon allostimulation. We therefore consider the fact that resting 'high' T cells do not support engraftment, an indication that alloresponse and graft facilitation may be inseparable. In addition, resting 'high' T cells do not influence outgrowth of an immunogenic malignancy after transplantation, which may be an indication that GvDH and GvL effects are not separable either. Taking into account that 'high' cells have the potential to respond to pathogens in vitro, the beneficial 'in vivo' effect using 'high' T cells for transplantation may be the control of infection, for example, by adding these 'high' T cells to haploidentical BM grafts.
Insignificant tumor control mediated by 'high' T cells could be explained by a series of considerations: first, P815B7 may share a panel of antigens with DBA/2 splenocytes recognized by BALB/c T cells when stimulated in vitro. This is documented by recognition of P815B7 by BALB/c T cells stimulated against DBA/2 spleen and also described in humans, where leukemia-reactive T cells also respond against Ph À stimulators in CML patients after allogeneic transplantation. 39 Second, P815B7 grows as a solid tumor containing stromal cells of host origin (data not shown). As stromal cells and the immune response against them are critical for tumor control mediated by T cells, 40, 41 the 'high' fractiontolerant towards cells of recipient origin -may not recognize stromal cells, which may interfere with tumor rejection.
Third, 'high' T cells are tolerant towards host T lymphocytes, which therefore persist. Blazar et al. 42 suggest an attenuation of GvHD when host-type T lymphocytes are present, owing to generation of anti-donor CTL effector cells; so inefficient depletion of host T cells may hamper tumor rejection.
In conclusion, based on the results presented here, we do not consider resting 'high' T cells as capable of mediating a significant GvL effect and facilitating engraftment but tolerant towards the host organism, responsive towards infectious antigens and allow B-cell development. On the other hand, preselecting proliferating 'low' T cells responding against the underlying malignancy that are specific for a more limited spectrum of antigens -here achieved by using P815B7 tumor cells as stimulator in vitro -reduces the extent of GvHD in the minor mismatch model. As leukemia-reactive T cells have the potential to control the underlying malignant disease, 43, 44 this may be a promising approach to reduce GvHD while maintaining the GvL effect. This is in line with our observations in Rag1 À/À mice, which survive without signs of GvHD after reception of alloreactive T cells that proliferated in response to lymphatic cells in vitro ('low'). Lymphatic cells are not present in the Rag1 À/À host, therefore the transferred allogeneic T cells are not stimulated 23 but present throughout the observation time. Challenging these mice with recipient lymphatic antigens induces a lethal GvHD, which proves immunocompetence of the transplanted T-cell fraction and suggests that large doses of antigen -for example, provided by a leukemia relapse -will induce GvHD by 'narrowed-spectrum' T cells. This is in line with reports of Falkenburg et al. 43 using leukemia-specific T-cell lines that confer disease control but also induce GvHD. Our results in the Rag1 À/À system also question whether response against a certain cell type (GvL) will occur without the induction of GvHD.
Based on the results presented here, we now favor and will further explore the in vitro isolation of leukemiareactive T cells ('CFSE-low') as a rapid and reliable method to narrow down the spectrum of T-cell reactivity, aiming at the reduction of GvHD without losing the GvL effect.
